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Introduction:To generalize safety and efficacy findings, it is essential that diverse pop-
ulations are well represented in Alzheimer’s disease (AD) drug trials. In this review, we
aimed to investigate participant diversity in disease-modifying AD trials over time, and
the frequencies of participant eligibility criteria.
Methods: A systematic review was performed using Medline, Embase, the Cochrane
Library, and Clinicaltrials.gov, identifying 2247 records.
Results: In the 101 includedAD trials, participantswere predominantlyWhite (median
percentage: 94.7%, interquartile range: 81.0–96.7%); and this percentage showed no
significant increase or decrease over time (2001–2019). Eligibility criteria such as
exclusion of persons with psychiatric illness (78.2%), cardiovascular disease (71.3%)
and cerebrovascular disease (68.3%), obligated caregiver attendance (80.2%), and spe-
cific Mini-Mental State Examination scores (90.1%; no significant increase/decrease
over time) may have led to a disproportionate exclusion of ethnoracially diverse indi-
viduals.
Discussion: Ethnoracially diverse participants continue to be underrepresented in AD
clinical trials. Several recommendations are provided to broaden eligibility criteria.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and nomodifications or adaptations aremade.
© 2021 The Authors. Alzheimer’s & Dementia published byWiley Periodicals LLC on behalf of Alzheimer’s Association.
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1 INTRODUCTION
Although ethnoracially diverse individuals are at an increased risk of
developing Alzheimer’s disease (AD) dementia,1–4 these populations
are systematically underrepresented in AD clinical trials.5–7 To gener-
alize safety and efficacy findings from drug trials to the general pop-
ulation, it is essential to include a diverse population, as differences
in pharmacokinetics and pharmacodynamics across diverse popula-
tions may impact treatment effect and safety;8,9 for instance, drug
metabolism rates may differ.6 The lack of diversity among clinical trial
participants is often attributed to enrolling and retaining practices,
such as recruitment strategies that do not account for factors that play
a role in diverse populations, including mistrust and worry because
of historical racism in medical research or the possibility of injury or
complications.10
Although recruitment factors should be taken into consideration,
other explanations need to be considered as well, especially because
a number of studies have indicated that people from underrepre-
sented populations may be equally willing to participate in health
research.11,12 One important potential cause is that there are inherent
features of AD-clinical trial eligibility criteria that lead to a dispropor-
tionate and systemic exclusion of underrepresented populations.13,14
In 1997, Schneider et al.14 demonstrated that applying the eligibility
criteria of typical AD clinical trials to a Californianmemory clinic popu-
lation led to a systematic underrepresentation of peoplewho are older,
female, ethnoracially diverse, lower educated, and less wealthy; they
provided several suggestions to improve provisional eligibility, such as
a wider range of allowed scores on theMini-Mental State Examination
(MMSE15) or by allowingmore patients with (mild) behavioral and psy-
chological symptoms to participate.
This systematic review aims to take a closer look at diversity in clin-
ical trials and eligibility criteria. The first goal was to investigate the
level of participant diversity inADclinical trials in the decades after the
publication of Schneider et al.14 The second goal was to identify which
eligibility criteria have beenused andhow these eligibility criteriawere
defined. Third, we aimed to assess whether the use of criteria related
to cognitive and neuropsychiatric instruments such as theMMSE have
changed over time, as these were highlighted by Schneider et al.14 as
particularly problematic. Last, we will discuss how some eligibility cri-
teria may have affected diversity levels in AD clinical trials.
2 METHODS
2.1 Search strategy
We performed a systematic review using Medline (which includes
PubMed), Embase, the Cochrane Library, and ClinicalTrials.gov, with-
out restrictionson theyear of publicationor locationof the trial. Search
terms included different terms for AD and mild cognitive impairment
(MCI), terms referring to disease-modifying drugs, terms related to
amyloid beta (Aβ) and tau, and different terms for phase II and phase
III trials (for the complete lists of the search terms used, see Text S1 in
supporting information). Studies were included up to December 2019.
Two independent authors screened all collected study data (JS and SF).
Disagreement was resolved by a consensus agreement together with
JMP. The PRISMA (Preferred Reporting Items for Systematic Reviews
and Meta-Analyses) guidelines16 were followed, except for an assess-
ment of the risk of bias—this step was omitted, as the aim was not to
reviewor summarize the treatment effect reported in the includedclin-
ical trials.
2.2 Eligibility criteria
To be included in the review:
1. The study needed to be a planned, ongoing, completed, or early ter-
minated phase II or phase III drug trial for patients with AD demen-
tia, prodromal AD (early AD stage 317), or amnesticMCI (aMCI).
2. The experimental drug was a disease-modifying treatment.
Disease-modifying was defined as targeting the pathogenic steps
in the Aβ or tau pathways. This includes passive vaccination, mon-
oclonal antibodies, agents disrupting accumulation or aggregation,
and agents increasing clearance. As no agreed-upon standards
are currently available that definitively delineate which drugs are
considered disease-modifying, drug mechanisms were confirmed
by consulting relevant literature (e.g., Galimberti and Scarpini18)
and examining trial features (e.g., outcomes measuring amyloid
clearance).
To adequately capture recent developments; collate study results;
and provide a clearly delineated, concise set of recommendations,
we focused on a homogeneous set of trials and excluded several
other types of trials and study populations from this review. First, we
excluded studies focusing on other forms of dementia. Second, we
excluded AD prevention trials (e.g., lifestyle intervention trials) and
studies in preclinical AD (early AD stages 1–217) as these types of tri-
als present with unique challenges and eligibility criteria. Third, we
excluded studies focused on symptomatic treatment of AD, including
studies of acetylcholinesterase inhibitors—tacrine, donepezil, rivastig-
mine, and galantamine—and memantine. Fourth, we excluded tri-
als investigating herbal and dietary treatments (e.g., vitamin supple-
ments, olive oil, huperzine). Conference abstracts, dissertations, com-
ments, editorials, book chapters, white papers, and reviews were also
excluded.
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2.3 Data extraction
For each included study, all available study protocol sources—that is,
published papers or National Clinical Trial (NCT) database, European
Union Drug Regulating Authorities Clinical Trial Database (EudraCT),
and Australian New Zealand Clinical Trial Registry (ANZCTR) clinical
trial registrations—identified in the search were used for data extrac-
tion.When available, the year that the studywas first posted, the study
phase, the investigational drug, the inclusion and exclusion criteria, the
number of recruited participants, and participant demographics were
recorded. Information was compiled from all available sources to cre-
ate themost complete accountof each study’s designand study sample.
2.4 Data analysis
Participant eligibility criteria were divided into three main categories:
(1) criteria related to medical conditions; (2) criteria related to under-
going specific study procedures, such as neuropsychological tests and
brain scans; and (3) criteria based on diagnostic tests and question-
naire outcomes. Analyses were mostly descriptive. We used Cochran-
Armitage trend tests (using the CATT package in R) to assess trends
over time for binary variables, that is, whether a criterion was used in
the trial or not. Spearman correlations were used to analyze associa-
tions between the study start year and continuous variables.
3 RESULTS
We identified 2247 records. The review process is summarized in
the PRISMA flowchart in Figure 1. After deduplication, 1777 records
remained; these records were screened on title and abstract. If the
topic of the abstract fell within the criteria, but there was insufficient
information on drug mechanism and/or trial phase, we reviewed the
full text. A total of 506 records (clinical trial registrations or papers)
were assessed in full for eligibility. A total of 17 NCT registrations, 35
EudraCT registrations, and one ANZCTR registration linked to pub-
lished papers were retrieved manually. For three studies for which a
published paper was available, we could not identify a clinical trial reg-
istration.
A total of 101 trialswere included in this review.Weextracted infor-
mation about these trials from 181 unique papers and clinical trial reg-
istrations, as well as from 21 full protocols that were attached to the
included papers or clinical trial registrations. The full protocols were
not publicly available for the remaining trials. The sample consisted of
67phase II trials and34phase III trials, investigating47different drugs.
The studies covered 2001 to 2019, during which 79 studies had fin-
ished recruitment, and 22 studies had not yet commenced orwere reg-
istered as active/recruiting. A listing of the included papers and clinical
trial registration numbers is provided in Table S1 in supporting infor-
mation. Several of the eligibility criteriaweremore prevalent in studies
forwhich a full protocolwas available as opposed to studies forwhich a
full protocol was not available (see Text S2 in supporting information).
RESEARCH INCONTEXT
1. Systematic review:We reviewed the published literature
and clinical trial registries to examine participant diver-
sity in Alzheimer’s disease drug trials, as well as develop-
ments in eligibility criteria for these trials. The trials cov-
ered a time period from 2001–2019.
2. Interpretation: Study samples in AD trials were predom-
inantly white, and participant diversity did not change
over time. Several characteristics of eligibility criteriamay
lead to systemic exclusion of diverse populations, such as
theuseof specific cognitive tests, requirements regarding
language fluency, education, or caregiver attendance, and
the exclusion of patients with comorbid conditions.
3. Future directions: This review highlights several eligibil-
ity criteria that requiremore research/consensus, such as
how to best operationalize medical conditions and which
cognitive and clinical tests may best be used in diverse
populations. In addition, it highlights the need for revision
of race/ethnicity categorization and for better reporting
of diversity-related data.
3.1 Diversity in clinical trial participants
Of the 101 trials, most had one or more study site(s) in North America
(79.2%) or Europe (60.4%), and less frequently Asia (36.6%), or Ocea-
nia (32.7%); even fewer trials included study sites in South America
(14.9%) or Africa (6.9%). Race/ethnicity data of the enrolled partici-
pants was available for less than half of the clinical trials (46 stud-
ies, 45.5%). Of these trials, 10 (9.9%) reported only the percentage
of White participants without specifying percentages for any other
ethnoracial groups, and four (4.0%) included White participants only.
Race/ethnicity data was available for 58.2% (46/79) of the studies
that were registered as completed or early terminated. When looking
specifically at trials for which a published paper was available, 75.5%
reported any race/ethnicity data (40/53). Different race/ethnicity cat-
egorizations were used across studies. Trials in Clinicaltrials.gov often
reported race and/or ethnicity according to the National Institutes
of Health/Office of Management and Budget (NIH/OMB) categories.
Although few papers explicitly reported using the NIH/OMB catego-
rization, a selection of these categories was often used in papers as
well, whereas other categorizations were used very infrequently—one
trial conducted acrossAsia, Europe,NorthAmerica, andSouthAmerica
reported numbers for “Caucasian,” “African,” “Hispanic,” “East Asian,”
and “West Asian” participants, and a paper about a trial conducted
in the UK and Singapore reported the numbers of “Afro-Caribbean,”
“Asian,” and “Caucasian” participants.
The median reported percentage of White participants in all stud-
ies was 94.7% (interquartile range [IQR]: 81.0–96.7%). This percent-
age of White participants was invariably high across both trials that
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F IGURE 1 Results of database searches and selection process
did and those that did not use specific eligibility criteria (see Table S2
in supporting information). Only seven studies reported the number
of participants with a Latinx (Latina/o) ethnic background (median:
5.6%, IQR: 4.2–11.4%); specifically, 20.0% of the trials that included a
North American site for which race/ethnicity data was available (7/35)
reported the number of participants with a Latinx ethnic background.
Data regarding (non-)Latinx backgroundwas often presented separate
from the number of participants in each racial group; it was therefore
unclear howmanyparticipantswith a Latinxbackgroundwere included
across racial groups (e.g., Latinx–White). The median percentage of
Black/AfricanAmericanparticipantswas1.2% (IQR: 0.4–1.7%), and the
median percentage of Asian participants was 4.4% (IQR: 0.3–17.3%;
NB: three studies fromAsia had samples consisting of 100%Asian par-
ticipants). The median percent of other or multiracial participants was
0.9% (IQR: 0.0–1.9%).
We found no statistically significant relationship between the per-
centage of White participants and the study start year (ρ = –.26, P =
.09). Of the studies for which a published paper was available 47.2%
(25/53) reported the number of people who did not meet the eligi-
bility criteria. Only 17.0% (9/53) specified which criteria most fre-
quently were the cause of participant exclusion. Although one study
(NCT00105547) reportedwhether the excluded and included patients
differed on age and sex, none of the studies reportedwhether included
and excluded participants differed on race/ethnicity.
Of the studies reporting race/ethnicity, none explicitly referred to
socioeconomic status (SES), while 41.3% (19/46) reported on the par-
ticipants’ education level. We extracted the mean education level of
the total sample for each of these studies and calculated the aver-
age of the reported means across placebo and intervention groups for
studies that did not report the total sample mean. The average mean
number of years of education across these studies was 13.3 years, and
a higher mean level of education was significantly correlated with a
higher percentage of White participants included in the trial (ρ = .61,
P= .02).
FRANZEN ET AL. 5
3.2 Eligibility criteria
3.2.1 Criteria related to medical conditions
The frequency of exclusion criteria related tomedical conditions is dis-
played in the first columns of Table 1, ranked frommost prevalent (top)
to least prevalent (bottom). In the remaining columns to the right, we
present the prevalence of these medical conditions in several ethnora-
cial groups to provide context for the potential impact on ethnoracial
diversity of participants. In addition to ethnoracial groups within the
United States19 (non-Latinx White, Latinx, non-Latinx Black, Ameri-
can Indian/AlaskaNative), wehave includedprevalence estimates from
the Indigenous Australian population20 as an example to illustrate the
potential impact of eligibility criteria on an international scale (see note
to Table 1 for additional sources used to compile this table).
Non-AD neurological diseases and (major) psychiatric disorders
were used as an exclusion criterion in more than three quarters of
the included AD trials (Table 1, column 3), followed by cardiovascu-
lar disease (71.3%) and a history of cerebrovascular disease (68.3%).
The last five columns of Table 1 demonstrate that the prevalence of
some medical conditions is higher in either non-Latinx Black US res-
idents, Latinx US residents, American Indian/Native Alaskan US resi-
dents, or IndigenousAustralians than in non-LatinxWhiteUS residents
or non-Indigenous Australians: diabetes, major psychiatric disease,
cerebrovascular disease, renal disease, alcohol/substance use disorder,
liver disease, higherweight/bodymass index (BMI), and human immun-
odeficiencey virus (HIV) diagnosis rates. For diabetes, studies some-
times referred to specificHbA1c levels, but these levels varied substan-
tially from<6.0% to<9.0%; other studies included “insulin dependent”
diabetes, “poorly controlled” diabetes, or merely “diabetes.” Studies
with a BMI criterion mostly required participants to have a minimum
BMI of 18 or higher, but the upper cut-off value varied considerably
from 28 to 40.Weight criteria specified a minimumweight of between
35 and 45 kg (≈77–99 pounds), mostly with a maximum of 120 kg
(≈265pounds). For hepatic disease, specific alanine transaminase (ALT;
1.5–3 times upper limit of normal, or ULN), aspartate transaminase
(AST; 1.5–3 times ULN), and/or bilirubin (1.5–2.5 times ULN) cut-
off levels were generally defined. For renal conditions, some studies
referred to specific levels of creatinine clearance, whereas others only
described “severe” renal disease, “impaired renal function,” or specified
dialysis requirement as the exclusion criterion.
3.2.2 Criteria related to study procedures
Caregiver attendancewas themost prevalent criterion related to study
procedures (80.2%, see Table 2), which often specified that the same
caregiver had to attend all study visits and sometimes that the care-
giver either had to live at the patient’s home or had to visit a minimum
number of times (range: <1–5 times/week) or hours per week (range:
4–24 hours/week). Some studies were more flexible, for example, by
requiring the caregiver to accompany the patient only on key follow-
up visits and allowing the patient to be accompanied by a “delegate” on
the other visits. Written informed consent (52.5%) and a contraindica-
tion to undergoing positron emission tomography (PET)/magnetic res-
onance imaging (MRI; 51.5%)were used as a criterion in themajority of
the included AD clinical trials.
Of the 19 studies using an education criterion, eight studies also
allowed a work history consistent with no intellectual disabilities. For
language fluency, most studies required fluency in the test language
(n = 11), in the “local” language (n = 11), or in English (n = 8), while
four studies allowed fluency in one of a number of languages. One
study allowed fluency in any language with sponsor approval, as long
as (1) staff were also fluent in that language, and (2) required study
documents were available in that language. A subset of studies (14.9%)
included a criterion whether patients or patient–caregiver dyads were
likely to complete the study in the opinion of the investigator; an oper-
ationalization of this criterion was not provided.
3.2.3 Criteria related to diagnostic tests and
questionnaires
Cognitive tests, batteries, or screeners were used as an inclusion cri-
terion in nearly all studies, with little variety in the tests that were
used; the MMSE score was a criterion in over 90% of the stud-
ies (Table 3). Aside from the MMSE, a handful of other screening
tests/short batterieswere used, such as the Repeatable Battery for the
Assessment of Neuropsychological Status (RBANS21), the Alzheimer’s
Disease Assessment Scale-Cognitive Subscale (ADAS-Cog22), and the
Montreal Cognitive Assessment (MoCA23). Additionally, some stud-
ies used memory-specific tests: the Free and Cued Selective Remind-
ing Test (FCSRT24), tests from the Wechsler Memory Scale–Revised
(WMS-R25), and the International Shopping List Test (ISLT26). One
study used different cut-off scores for the test they used (WMS-R) to
correct for education (0–7, 8–15, and ≥16 years); none of the other
studies described different cut-offs based on demographic or sociocul-
tural characteristics known to impact cognitive test performance (e.g.,
age, sex, ethnicity, quality of education, acculturation, etc.).
In addition to cognitive tests, roughly one-third of the trials used the
Clinical Dementia Rating (CDR27) global score as a criterion. A simi-
lar proportion of studies used a measure of psychiatric symptoms as
part of the eligibility criteria. For depression, the 15-item version of
the Geriatric Depression Scale (GDS28) was usedmost often, as well as
the Hamilton Depression Rating Scale.29 The allowed range of scores
for the GDS was relatively homogeneous across studies: the majority
of studies (n = 22, 88% of studies with GDS) included patients with a
score below 6 or 7, one study used the original 30-item version and
used a cut-off score of ≤10, and two studies using a cut-off of <8 did
not specifywhether the long or short version of theGDSwas used. The
Columbia Suicide Severity Rating Scale30 was used a few times, but the
majority of studieswith a suicide risk criterion left the interpretation of
this criterion to theopinionof the investigator (in contrastwith depres-
sive and cognitive symptoms).
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Other neurological disease 81 80.2% — — — — —
Psychiatric disorder 79 78.2% 6.9% 9.4% 9.7% — 12% (9.6%)
Cardiovascular disease 72 71.3% 11.5% 8.2% 10.0% 14.6% 13% (1.2x)
Cerebrovascular disease 69 68.3% 2.6% 2.5% 3.9% 3.0% —
-Hachinski ischemia scale
score>4
53 52.5% — — — — —
- Cerebrovascular evidence
onMRI
48 47.5% — — — — —
Childbearing/conception 62 61.4% — — — — —
Unspecified systemic illness 62 61.4% — — — — —
Alcohol or drug abuse 59 58.4% 8.4% 8.6% 7.4% 14.9% 18% (19%)
Vitals or lab abnormalities 53 52.5% — — — — —
Infections/infectious diseases 50 49.5% — — — — —
-HIV status‡ 26 25.7% 4.8‡ 16.4‡ 39.2‡ 7.7‡ 5.5‡ (4.5‡)
Liver disease 48 47.5% 1.7% 2.7% 1.1% 2.5% 15%-23%
(1.4x-2.1x)
Autoimmune disease 47 46.5% 22.0% 16.8% 21.0% 30.6% 10.0% (1.1x)
Renal disease 46 45.5% 2.0% 2.2% 3.1% — 3.0% (≈3.7x)
Seizure disorder 44 43.6% — — — — —
Cancer 41 40.6% 9.1% 4.2% 5.1% 7.1% 1.7% (1.5%)










Endocrine dysfunction 25 24.8% — — — — —
Brain/head trauma 25 24.8% — — — — —










Weight or BMI cut-off 21 20.8% 31.0% 34.9% 38.0% 48.1% 37% (1.6x)
Gastrointestinal disease 18 17.8% 5.7% 4.3% 4.9% 8.3% —
Excessive smoking (≥20
cigarettes per day)
9 8.9% — — — — —
CNS inflammation 8 7.9% — — — — —
Systemic inflammation 6 5.9% — — — — —
Abbreviations: BMI, bodymass index; CNS, central nervous system; HIV, human immunodeficiency virus; MR, magnetic resonance imaging; n-L, non-Latinx.
*2018 US National Health Interview study data19 and 2015 Australian Institute of Health and Welfare data are presented20 (unless otherwise specified),
providing prevalence rates for the following specific conditions within the broader categories specified in the first column: psychiatric disorders=moderate
to severe depressive symptoms (US78) versus feeling depressed (AUS); cardiovascular disease= any; cerebrovascular disease= stroke; alcohol or drug abuse
= substance dependence or abuse (US79) versus lifetime risky alcohol consumption (AUS); infections – HIV status (US80); autoimmune disease = arthritis
diagnosis; renal disease = weak or failing kidneys (USA) versus chronic kidney disease stages 3-5 (AUS); liver disease = any (US) versus abnormal ALT/GGT
(AUS); cancer= any; weight or BMI= obesity; gastrointestinal disease= ulcers (duodenal, stomach, peptic).
†In parentheses: times increased risk compared to non-Indigenous Australians or prevalence rate in non-Indigenous Australians.
‡Diagnosis rate per 100,000.
§Respiratory illness= current asthma (top) and chronic bronchitis (bottom).
¶Diabetes= diagnosed (top) versus diagnosed and undiagnosed combined (bottom81).
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TABLE 2 Frequencies of criteria related to undergoing study
procedures
Criterion frequency in
all trials (N= 101)
Caregiver attendance 81 80.2%
Written informed consent 53 52.5%
Contraindication toMRI/PET 52 51.5%
Adequate sensory abilities 42 41.6%
Language ability 35 34.7%
Residence in the community 35 34.7%
Caregiver consent 28 27.7%
Education requirement 19 18.8%
Reading or writing ability 19 18.8%
Determined likely to complete 15 14.9%
Recent hospitalization 4 4.0%
Abbreviations: MRI, magnetic resonance imaging; PET, positron emission
tomography.














Eastern CooperativeOncology Group status 1 1.0%
FAQ 1 1.0%
PSYCHIATRICASSESSMENTS
Geriatric Depression Scale 25 24.8%
Hamilton Depression Rating Scale 6 5.9%
Other depression instrument 1 1.0%
C-SSRS 5 5.0%
Other/unspecified suicide or self-harm risk scale 14 13.9%
Abbreviations: ADAS-Cog, Alzheimer’s Disease Assessment Scale-
Cognitive Subscale; C-SSRS, Columbia Suicide Severity Rating Scale; CDR,
Clinical Dementia Rating; FAQ, Functional ActivitiesQuestionnaire;MMSE,
Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment;
RBANS, Repeatable Battery for the Assessment of Neuropsychological
Status.
*Includes Free andCued SelectiveReminding Test (FCSRT),WechslerMem-
ory Scale-Revised (WMS-R), and International Shopping List Test (ISLT).
F IGURE 2 Changes inMini-Mental State Examination (MMSE)
upper and lower cut-off scores (midpoint in dotted line)
Diagnostic tests and screeners: the use of theMMSE, CDR, and GDS
over time
Additional Cochran-Armitage trend analyses of the use of the MMSE
revealed that the study start year did not differ between studies with
or without anMMSE-eligibility criterion (Z= 0.14, P= .89); that is, the
MMSE cut-off scores were not used significantly less (or more) often
with time. As displayed in Figure 2, the cut-off score for the MMSE
increased over time (MMSE lower limit ρ=0.53,P< .001;MMSEupper
limit ρ = 0.48, P < .001). Furthermore, the range of allowed MMSE
scores narrowed over time (ρ = –0.44, P < .001). Similar to the MMSE,
theCochran-Armitage trend test showed that therewasno statistically
significant increaseor decrease in theuseof theGDSby studyyear (Z=
0.0, P= .99); the CDR, however, was used significantlymore frequently
in later years (Z= –2.48, P= .01).
4 DISCUSSION
In this systematic review, we aimed to (1) investigate the level of par-
ticipant diversity in AD clinical trials targeting Aβ and tau; (2) iden-
tify which eligibility criteria have been used and how these criteria
were defined; and (3) discover whether the use of criteria related to
cognitive and neuropsychiatric instruments changed over time. The
results showed that study samples were predominantly composed of
White individuals, and ethnoracial diversity levels did not show a sig-
nificant increase (or decrease) over time. Some of the most frequently
reported criteria were the exclusion of participants with non-AD neu-
rological disease, psychiatric illness, cardiovascular and cerebrovascu-
lar disease, obligated caregiver attendance, and cognitive impairment
as defined by a specific score on theMMSE. TheMMSE was used in an
overwhelming majority of cases as the main cognitive eligibility crite-
rion andwas used consistently over time,with cut-off scores increasing
over theyears, butwith the rangeof allowedscoresdecreasingover the
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TABLE 4 Issues with eligibility criteria of clinical trials and recommendations
Issue/criterion Recommendations
Overarching issues
-Race and ethnicity often were not reported
-Current race/ethnicity definitions not globally suitable
-It is unclear howmany diverse patients are invited,
screened, and excluded
-It is unclear which criteria lead to exclusion
-Criteria from phase II copied to and expanded on in phase III
-Improve reporting
-Critically examine and improve definitions of race/ethnicity
-Improve reporting
-Improve reporting
-Revisit/revise all criteria in moving from phase II to phase III
Criteria related tomedical conditions
-Imprecise/unspecific definitions of medical conditions
-Variation in cut-offs for specific medical conditions
-It is unclear if race corrections should be used or not
-Exclusion of all patients with amedical condition regardless
of past/present health status
-Questionable safety of drugs for patients withmedical
conditions due to exclusion
-Use validated, internationally recognized clinical classifications (of disease staging)
-Organize expert consensusmeetings to determine appropriate cut-offs in AD research
-Organize expert consensusmeetings to determinewhether andwhen to apply race
corrections
-Includemore patients who can safely participate, for example, persons living with HIV
who aremedically stable and have a non-detectable viral load
-Use expansion cohorts to study safety
Criteria related to study procedures
-Language fluency as a barrier to participation
-Lower educated individuals often excluded
-Risk of compliance stereotyping if “likely to complete” is not
defined
-Caregiver attendance as a barrier to participation
-Written informed consent as a barrier in persons with
limited literacy/education
-Allow fluency in any language if adaptedmaterials and staff speaking that language are
available
-Allow persons with a work history consistent with no intellectual disabilities (ID) to
participate
-Investigate other ways to screen for ID
-Define “likely to complete” before trial
-Allow others to accompany patient on subset of visits
-Plan appointments outside business hours
-Explore remote interviewing options
-Explore alternatives for written informed consent, such as video informed consent
Criteria related to neurocognitive and neuropsychiatric
measures
-MMSE is unsuitable for diverse populations
-CDRmay be biased due to cultural differences
-Consider alternative, more widely applicable tests
-Use differentMMSE cut-offs depending on education and other relevant variables
-Consider adaptations to the instrument/questions
-Provide additional training to staff
Abbreviations: AD, Alzheimer’s disease; CDR, Clinical Dementia Rating;MMSE,Mini-Mental State Examination.
years. The criteria related to medical conditions and study procedures
oftenwere notwell operationalized and cut-off scoreswere oftenwide
ranging. In addition to these main aims, our goal was to discuss how
these eligibility criteria may have affected diversity levels. In the fol-
lowing paragraphs, we will discuss the main outcomes of this review
and provide recommendations for future clinical trials, an overview of
which can be found in Table 4.
We could not retrieve race/ethnicity data for more than half of the
studies included in this review; for those studies for which a paper
was published, a little over three quarters reported race/ethnicity data.
This is somewhat higher than in a review of cholinesterase inhibitors
andmemantine randomized controlled trials (59.2%5). The studies that
reported race/ethnicity data included an overwhelming majority of
White participants (≈95%), and no significant increase or decrease in
this ratio was observed over time. For most trials, data regarding Lat-
inx ethnicity was not reported, and in the handful of cases in which it
was described, it was presented separately from the numbers by racial
group. It was therefore not possible to determine how many Latinx
versus non-Latinx participants were included, and whether these pro-
portions may have changed over time. However, based on the studies
that did report the number of Latinx participants, as well as the data
from Black, Asian, and other racial groups, it seems unlikely that Lat-
inx participants were well represented. This lack of diversity, as well as
the underreporting of Latinx background are particularly notable for
studieswith aNorthAmerican site (79.2%), given the rapidly increasing
diversification of theUnited States during this reviewperiod.Whitfield
et al.31 describe how, as the ratio of White participants to other eth-
noracial groups increases, the statistical power to detect group differ-
ences decreases drastically, and samples will typically have to include
a larger proportion of diverse ethnoracial participants than a repre-
sentative sample of the general population (e.g., more than 15% Black
participants in the sample). As it stands, the limited percentage of
FRANZEN ET AL. 9
ethnoracially diverse individuals precludes sufficiently powered anal-
yses of safety and efficacy across ethnoracial groups. In addition, cur-
rently used racial/ethnic categories themselvesmay need to be revised
to fully represent global diversity—for example, categorizing all indi-
viduals fromEurope,NorthAfrica, and theMiddle East as “White” does
not do justice to the diversity within and between persons originating
from these regions.
Our results showed that trials targeting Aβ or tau in AD often pro-
vide unclear definitions of their eligibility criteria; these imprecise def-
initions, such as “diabetes” or “impaired renal function” (not further
specified), likely result in the exclusion of all or most patients with
a specific medical condition. When specific ranges on indices of cer-
tain medical conditions were provided, such as BMI or ALT/AST lev-
els, the allowed ranges differed substantially between studies. There
thus seems to be a lack of consensus on how these conditions are best
defined in the context of Aβ and tau trials. These ill-defined eligibil-
ity criteria may particularly affect the inclusion of underrepresented
populations that are characterized by health disparities. Kim et al.32
made several suggestions to broaden inclusion criteria in oncology tri-
als that may provide inspiration for AD trials. One of these recommen-
dations is to include persons living with HIV (PWH) based on current
and past CD4+ and T-cell counts instead of excluding all PWH—unless
antiretroviral therapy is expected to interact with the investigational
product. Additionally, onemight take into considerationwhether PWH
are medically stable and whether they have a (non-)detectable viral
load. Furthermore, Kim et al.32 provided examples of how to improve
the clarity of the definitions used in clinical trials eligibility criteria,
such as the use of validated clinical classifications (of disease staging)
as opposed tomore generic definitions.
With regard to the impact of criteria related to medical conditions
on the inclusion of ethnoracially diverse groups specifically, it is still
uncertain if, how, and when race corrections should be used to eval-
uate various clinical laboratory results as indicators of specific medi-
cal conditions, such as indicators of kidney functioning33 and several
other common laboratory values.34 Although such race corrections
could potentially make the process of inclusion in clinical trials more
inclusive, they may also inadvertently perpetuate or amplify existing
disparities.35 The field is in need of expert guidance to reach a consen-
sus onwhether andwhen to apply these race corrections.
Criteria related to undergoing study procedures were commonly
part of the eligibility criteria. In the following paragraphs, the eligibility
criteria related to language, education, caregiver attendance, written
informed consent/reading and writing abilities, and whether patients
are considered likely to complete the study, are discussed in more
detail, specifically in the context of the inclusion of diverse individuals.
First, language requirements, such as fluency in the English lan-
guage, were included in more than one third of the clinical trials.
Dependingon their definition, specific language requirementsmay lead
to disproportionate exclusion of individuals from underrepresented
populations. The lack of guidanceonhow tohandle languagebarriers in
clinical trials was acknowledged as a problem by multicenter research
ethics committees in the UK.36 A more inclusive solution may be to
allow fluency in any preferred language, as long as the required test
materials are available in that language and there is a staff member
available who speaks the language to the degree necessary for cogni-
tive testing—as was allowed in one trial (NCT00676143). This would,
however, require the development/adaptation and validation of test
materials across a number of languages. In addition, it may be worth-
while to investigate if assessmentwith experienced formal interpreters
could be a viable option at study sites where the population is excep-
tionally diverse.
Regarding education, a minimum of 6 years of formal education was
often used as a criterion—sometimes stating this was to ensure that
patients with intellectual disabilities were not included. This criterion
is problematic for several reasons; first, many diverse elderly patients
across the world did not receive any formal education during child-
hood due to reasons other than intellectual disabilities—such as a lack
of financial means or a large geographic distance to educational facili-
ties (e.g., in first generation immigrants in Europe). Second, mandatory
primary education across the world has historically been variable—
although some countries required 6 years of primary education, others
may have required only 4 or 5. Therefore, years or level of education
cannot serve as a suitable proxy for intellectual disabilities in diverse
patients. Somestudies acknowledged thesebarriers byallowingpeople
with a work history consistent with no intellectual disabilities to par-
ticipate in the study. Future studies should focus on developingways to
screen for intellectual disabilities that do not result in the exclusion of
patients without intellectual disabilities who had limited access to for-
mal education.
Several studies included a criterion that patients should be likely to
complete the study. However, the interpretation of this criterion often
was not defined, requiring the investigator to make this judgment call.
Although such a criterion may be necessary to prevent costly missed
visits in clinical trials, especially for studies using PET-ligands, likeliness
to complete should be well defined at the outset. For example, a pro-
tocol may state that the patient and caregiver should complete a first
run-in period of a specific number of screening visits fully compliant
with the specified study procedures and in line with a specified time
schedule. If this criterion is left undefined, it may prove problematic, as
studies have indicated that participant selection may be influenced by
implicit bias of the clinicians, that is, compliance stereotyping.37
More than three quarters of the studies required some formof care-
giver participation, often explicitly stating caregivers had to engage
in frequent contact with patients—one study required caregivers to
spend at least 24 hours per week with the patient. In some diverse
ethnoracial groups, the main caregiver is often an adult child, rather
than a spouse,38–40 and previous research has indicated that adult chil-
dren are less likely than spouses to be eligible to participate alongside
patients in dementia clinical trials.41 Adult–child caregivers are more
likely to still be active in the workforce,39 potentially limiting their
opportunities to engage in frequent studyvisits due to thepractical and
financial burden of missed work. Researchers may provide more flexi-
bility by allowing others to accompany patients on a subset of visits; by
having appointments taking place outside of weekday business hours;
or by exploring options for remote administration of interviews, such
as over the phone or via video calls.39
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More than half of the AD clinical trials in this review explicitly
required written informed consent. Although this currently seems
to be the standard, requiring written informed consent will lead to
the exclusion of people with low literacy skills—either because these
patients will not be asked, or because they will be hesitant to sign a
document they have difficulty understanding. Globally, ≈781 million
adults are illiterate,with ahighprevalence in lower- andmiddle-income
countries,42 although disparities in literacy are also prevalent in some
underrepresented populations in high-income countries. For example,
so-called “guest workers” in Europe often received little if any for-
mal education,43,44 and Latinx adults—and to a lesser degree Black
and American Indian/Alaska Native adults—in the United States were
overrepresented in the “below basic” level on theNational Assessment
of Adult Literacy.45 To facilitate the enrollment of underrepresented
populations, informed consent procedures will have to be tailored to
patients and caregivers with low literacy skills. Over two decades ago,
the US Food and Drug Administration (FDA) described the possibility
of non-written consent procedures in illiterate English-speaking sub-
jects, in which an impartial third party cosigns the consent document,
preferably with a videotape recording.46 A recent study in a differ-
ent medical field (cardiology/endocrinology) has indicated that using
a video informed consent procedure can increase the enrollment of
patients from underrepresented populations.47 As an additional exam-
ple, in India, audiovisual recording of the informed consent procedure
has been mandatory since 2013, and standard operating procedures
have consequently been developed.48 AD researchwould benefit from
efforts to incorporate alternatives to written informed consent devel-
oped in other research areas that include diverse and vulnerable popu-
lations, as well as from initiatives examining the feasibility of integrat-
ing such approaches in AD research.
Regarding cognitive screening tests and questionnaires, we found
that the MMSE was used almost invariably as an inclusion criterion,
and its use remained stable over time, with cut-off scores even increas-
ing over the years. This is notable, given the fact that Schneider et al.14
warned about the use of the MMSE in dementia trials in 1997. There
is an abundant literature describing how MMSE-scores are substan-
tially influenced by literacy and education49–51 and likely also by cul-
tural background.50 In particular the subtests of orientation to time
and place, serial 7s, figure copy, writing, and reading will be substan-
tially influenced by someone’s educational and cultural background.52
Developing alternatives to written informed consent will only solve
half of the problemas long as the cognitive tests used for screening and
tomeasure primary and secondary outcomes require reading andwrit-
ing skills. Moving forward toward more valid and inclusive global clin-
ical trials will entail using other cognitive tests that are more suitable
for diverse populations. For instance, the RowlandUniversal Dementia
Assessment Scale (RUDAS53)—a test to assess the general level of cog-
nitive impairment—or the International Shopping List Test26—for the
inclusion of patientswithmemory impairment specifically—may be rel-
evant options for further study. Before any instrument is selected for
a clinical trial, it is imperative that a thorough review of the literature
is carried out to determine whether the instrument is a valid and reli-
able measure of cognition in all groups that are to be included in the
trial. As selection bias is often present in reliability/validity studies—
for example, by excluding persons with low education levels or limited
language fluency—it may be necessary to specifically check the demo-
graphic characteristics of these original study samples to ensure they
reflect the intended trial sample. At a minimum, trials can be made
more equitable by using different cut-off scores for groups with differ-
ent levels of education in cognitive screeners andmemory tests, aswas
done by one trial in this review (NCT00890890).
In addition to the MMSE, this study showed a rise in the use of the
CDR as an inclusion criterion. The CDR has considerable merits, but
researchers and clinicians need to be aware of possible cultural differ-
ences that may bias the results, such as (1) downplaying of cognitive
symptoms out of respect for older family members, (2) different per-
ceptions of what “normal” daily functioning may entail, (3) the need
for adaptations to questions relating to hobbies that may be uncom-
mon in some groups—for example, crossword puzzles—and social or
cultural practices, (4) thepotential influenceof traditional gender roles,
and (5) the potential influence of limited literacy on some activities of
daily life.54 Aside from the extensive training that is already needed to
administer the CDR in a reliable and valid way in the general popula-
tion, it is likely that additional training and/or adaptations to the instru-
ment itself are needed to make it more suitable for the assessment of
diverse populations across the globe.
In addition to these specific recommendations pertaining to criteria
related to medical conditions, undergoing study procedures, and cog-
nitive screeners and questionnaires, some general recommendations
may further improve inclusion of underserved populations in AD clini-
cal trials. In thedesignphase, theFDA55 specifically recommends revis-
iting and revising the criteriawhenmoving froma restrictive phase II to
a more inclusive phase III trial.32,55 Furthermore, they encourage the
inclusion of samples known as “expansion cohorts” in trials—consisting
of patientswith specific comorbidities thatmay not fit the inclusion cri-
teria for themain study—to determine the safety of doses in these pop-
ulations as well.32 Aside from changes to the trial design, more insight
can be gained into the mechanisms behind the underrepresentation of
diverse patients in clinical trials, if studies were to report the ethnora-
cial characteristics of all patients that (1) were considered for eligibil-
ity, (2) were invited, (3) were screened, and (4) were excluded/screen
failed. In addition, reports should provide specifications regarding the
eligibility criteria that weremost often the reason for exclusion.
Although not technically part of the CONSORT (Consolidated Stan-
dards of Reporting Trials) guidelines,56 a short summary of the main
reasons for exclusion may provide valuable insights to researchers
on the eligibility criteria that have the strongest effect on eligibil-
ity. This information was only provided in a handful of studies in this
review, and none of the studies specified whether there was a dis-
proportionate exclusion of patients from underrepresented popula-
tions. It therefore remains unclear whether there was a dispropor-
tionate exclusion of patients from these groups based on overly strict
eligibility criteria, or whether these patients were not invited in the
first place or did not consent to study participation after invitation.
For example, patients from underrepresented populations may expe-
rience geographical, financial, or logistical barriers that prevent them
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fromparticipating in research.55,57 Additionally, recruitment strategies
need to be tailored to suit the needs of underrepresented populations,
such as by investing in community-outreach programs, trust-building
initiatives, and cultural-sensitivity training.10,36,58,59 Financial support
from funding agencies and/or the trial sponsor to facilitate such ini-
tiatives may be needed. In addition, more general financial or regula-
tory incentives from funding organizations or governmental bodies to
actively enroll patients from underrepresented populations may fur-
ther improve inclusion, for example, similar to the changes in the field
of pediatrics, in which the Pediatric Research Equity Act (PREA) now
requires manufacturers to complete studies in children if a substantial
number of children is expected to use the drug.60
Although this review specifically examined race/ethnicity, we
acknowledge that race is a social construct and that health dispari-
ties are often driven by social determinants of health, such as edu-
cation, literacy, socioeconomic status, racially patterned social stress,
and access to care.61–63 Although some trials in this review with
race/ethnicity data reported the education level of the included partic-
ipants, none mentioned SES. This limited reporting of social determi-
nants of health is in line with a previous review in symptomatic treat-
ment of AD, in which no studies reported on variables such as lifetime
occupation, individual/household income, or wealth, and few stud-
ies on education.64 It remains unclear how these variables may have
affected enrollment of diverse participants in the trials included in this
review; however, participants are often recruited in memory clinics,
and these facilities may not be accessible to some underrepresented
groups, for example because of limited health literacy,65 or because
medical care is expensive and insufficiently covered by insurance.66
Several limitations to this review should be mentioned. Although
we did not exclude studies based on the language in which the record
was written, our study did not identify any articles that were not writ-
ten in English. Therefore, some local trials may have been missed. Sec-
ond, race/ethnicity data was not available for a substantial number
of studies, and the full protocols describing all eligibility criteria were
only available for about one fifth of the included trials. As can be seen
in the supporting information, the frequencies of the eligibility crite-
ria may differ between studies with and without a full protocol avail-
able, and the rates we presented in this review may be an under-
estimation of the actual frequencies. For example, it seems unlikely
that only slightly more than half of the clinical trials required writ-
ten informed consent, particularly as the studies without such a cri-
terion did not describe any alternative consent requirements. Like-
wise, trials that did not report race/ethnicity data may have included
even fewer diverse participants—or, less likely, more—than the studies
that did report race/ethnicity data. Third, in this review, we presented
data from diverse ethnoracial populations in Australia and the United
States alongside the frequencies of the eligibility criteria related to
medical conditions to provide the reader with a better sense of the
potential impact on diversity in clinical trials. These populations can-
not be seen as directly representative of all underrepresented popu-
lations across the world, and given that these data were obtained in
the general population, health disparities may actually be even more
systemic and striking when zooming in on elderly populations specifi-
cally. For example, the prevalence of overweight and obesity in indige-
nous populations in Australia is 35% in those aged 15 to 17, but rises
to 80% in those 55 and over.20 Although we only showed data from
the United States and Australia, similar health disparities are observed
in populations outside those two countries, such as across different
ethnoracial groups in Europe—particularly in the prevalence of dia-
betes, stroke, hypertension, and cardiovascular disease,67–69 but also
in kidney disease.70,71 Fourth, it is important to note that the data
based on Latinx American samples is based on a pan-Latinx construc-
tion of this population. These studies did not account for the signifi-
cant within-group variance that has important implications for health
disparities and cognitive test performance (e.g., origin/nativity [Mex-
ican, Puerto Rican, etc.], acculturation). Fifth, we only focused on Aβ
and tau trials in this review. Althoughmany of these recommendations
can likely also be applied to other types of trials across neurodegenera-
tive diseases, such as lifestyle trials likeWorld-Wide FINGERS,72 some
of these trials will come with their own unique challenges—such as a
lack of suitable cross-cultural instruments measuring social cognition,
language, and behavioral changes in frontotemporal dementia trials73
as well as issues regarding the applicability of the diagnostic criteria
for primary progressive aphasia subtypes across global languages, such
as Chinese.74 Last, we were unable to determine the direct effect of
each criterion on the representation of diverse individuals using infer-
ential statistics. Several factors precluded such analyses, such as the
fact that some criteria were used either very infrequently or invariably
(e.g., the MMSE, Table S2), as well as the fact that race/ethnicity data
wasnot reported for eachglobal region/country specifically, precluding
any comparisons of the makeup of the study samples with a priori dis-
ease estimates in the general populations in these countries/regions.
The contribution of each individual eligibility criterion to the under-
representation of diverse individuals across trials therefore remains
unclear—even more so given the underreporting of the main reasons
for exclusion.
Both federal law (Public Health Service Act §492B75) and NIH
policy76 require studies involving human subjects to address the
inclusion of “minorities,” and Alzheimer Europe77 similarly calls upon
researchers, ethics committees, and funders to address inequity in
research. This review illustrates that there is a continuous, systemic
underrepresentation of ethnoracially diverse groups in AD clinical tri-
als. Togeneralize safety andefficacydataofADclinical trials to thegen-
eral population,more diverse individuals need to be enrolled, andmod-
ifying or changing the eligibility criteria in AD clinical trials may play a
key role in reaching this goal.
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